Published in Cancer Res on August 01, 2004
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev (2010) 4.75
Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells in vitro and in vivo. Cancer Prev Res (Phila) (2013) 1.59
Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res (2008) 1.54
Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch (2005) 1.33
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 1.31
MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer (2013) 1.17
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer (2011) 1.01
Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol (2007) 0.99
Small molecule amiloride modulates oncogenic RNA alternative splicing to devitalize human cancer cells. PLoS One (2011) 0.99
ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A (2009) 0.97
Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors. PLoS One (2010) 0.93
Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation. J Cell Commun Signal (2012) 0.90
Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk. Proc Natl Acad Sci U S A (2005) 0.90
Identification of a novel function of CX-4945 as a splicing regulator. PLoS One (2014) 0.89
Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer. Oncotarget (2016) 0.84
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res (2013) 0.84
The tyrosine kinase sf-Stk and its downstream signals are required for maintenance of friend spleen focus-forming virus-induced fibroblast transformation. J Virol (2007) 0.83
The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas (2014) 0.80
Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. PLoS One (2012) 0.80
Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein. J Biol Chem (2014) 0.80
Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (2016) 0.79
A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells. Oncogene (2015) 0.78
Short-form RON overexpression augments benzyl isothiocyanate-induced apoptosis in human breast cancer cells. Mol Carcinog (2015) 0.78
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget (2015) 0.77
Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer. Int J Clin Exp Med (2015) 0.75
Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes Cancer (2016) 0.75
Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression. Int J Exp Pathol (2015) 0.75
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget (2016) 0.75
Prognostic significance of MST1R dysregulation in renal cell tumors. Am J Cancer Res (2016) 0.75
HRAS, EGFR, MET, and RON are recurrently activated by provirus insertion in MAV-2 retrovirus-induced liver tumors. J Virol (2017) 0.75
Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression. Chonnam Med J (2017) 0.75
A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer. Oncol Lett (2017) 0.75
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell (2003) 6.59
MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol (2010) 5.44
Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer (2002) 3.89
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. Nature (2002) 2.99
The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol (2002) 2.74
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev (2008) 2.41
CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature (2009) 2.13
The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 2.02
Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol (2005) 1.84
Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81
MicroRNAs impair MET-mediated invasive growth. Cancer Res (2008) 1.81
CCM2 mediates death signaling by the TrkA receptor tyrosine kinase. Neuron (2009) 1.79
The Met pathway: master switch and drug target in cancer progression. FASEB J (2006) 1.74
Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol (2010) 1.73
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer (2003) 1.69
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology (2013) 1.61
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res (2011) 1.52
Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab Invest (2008) 1.51
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res (2012) 1.51
DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med (2008) 1.49
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A (2006) 1.47
Glial TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia (2008) 1.44
To move or not to move? Semaphorin signalling in cell migration. EMBO Rep (2004) 1.42
Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest (2010) 1.41
Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol (2002) 1.40
Plexin-B3 is a functional receptor for semaphorin 5A. EMBO Rep (2004) 1.39
Hepatocyte growth factor and its receptor are required for malaria infection. Nat Med (2003) 1.37
The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37
Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol (2006) 1.37
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A (2011) 1.36
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res (2003) 1.34
Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations. Clin Cancer Res (2011) 1.32
p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling. J Cell Sci (2005) 1.31
miR148b is a major coordinator of breast cancer progression in a relapse-associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB J (2012) 1.27
Insight into 2-phenylpyrazolo[1,5-a]pyrimidin-3-yl acetamides as peripheral benzodiazepine receptor ligands: synthesis, biological evaluation and 3D-QSAR investigation. Bioorg Med Chem (2005) 1.26
Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res (2002) 1.26
CircuitsDB: a database of mixed microRNA/transcription factor feed-forward regulatory circuits in human and mouse. BMC Bioinformatics (2010) 1.26
An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25
AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J (2008) 1.24
Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum Mol Genet (2005) 1.21
The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res (2012) 1.21
Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res (2005) 1.20
Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem (2004) 1.16
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatr Genet (2009) 1.13
Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol (2005) 1.10
Functional regulation of semaphorin receptors by proprotein convertases. J Biol Chem (2003) 1.10
Cancer: the matrix is now in control. Nat Med (2005) 1.09
MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res (2006) 1.09
Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs (2010) 1.09
The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res (2010) 1.08
Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. Cancer Res (2007) 1.07
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res (2011) 1.07
Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res (2011) 1.06
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem (2010) 1.06
A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem (2008) 1.06
Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis. Cancer Res (2010) 1.05
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors. J Med Chem (2012) 1.03
Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal (2009) 1.02
A mouse model of pulmonary metastasis from spontaneous osteosarcoma monitored in vivo by Luciferase imaging. PLoS One (2008) 1.02
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res (2014) 1.02
Strain Doppler echocardiography can identify longitudinal myocardial dysfunction derived from edema in acute myocarditis. Int J Cardiol (2007) 1.01
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem (2010) 1.01
Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J Clin Invest (2009) 1.00
High frequency of MYH gene mutations in a subset of patients with familial adenomatous polyposis. Gastroenterology (2004) 0.99
The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J Exp Med (2008) 0.99
Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem (2006) 0.98
Invasive growth: a genetic program. Int J Dev Biol (2004) 0.98
Molecular analysis of the GNAS1 gene for the correct diagnosis of Albright hereditary osteodystrophy and pseudohypoparathyroidism. Pediatr Res (2003) 0.98
Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res (2004) 0.98
Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res (2005) 0.98
Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. Hum Mutat (2009) 0.97
The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis. Mol Biol Cell (2008) 0.97
ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A (2009) 0.97
"Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res (2008) 0.97
Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res (2002) 0.96
Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocr Pathol (2000) 0.96